Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 5/20 | 0.38 |
| ▸ | HTR2B | P41595 | 3/20 | 0.38 |
| ▸ | SOD3 | P08294 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13455832 | 0.82 | PDCD1 (0.44) | PDCD1CD274HTR2CHTR2BSOD3 | |
| SCHEMBL3548738 | 0.79 | PDCD1 (0.44) | PDCD1CD274HTR2CSOD3HTR2A | |
| SCHEMBL14925553 | 0.77 | PDCD1 (0.45) | PDCD1CD274HTR2CHTR2BSOD3 | |
| SCHEMBL16682646 | 0.76 | PDCD1 (0.48) | PDCD1CD274HTR2CHTR2BHTR2A | |
| SCHEMBL24873410 | 0.74 | — | — | |
| SCHEMBL23109989 | 0.74 | PDCD1 (0.40) | PDCD1CD274HTR2CHTR2BSOD3 | |
| SCHEMBL25085448 | 0.73 | PDCD1 (0.42) | PDCD1CD274HTR2CSOD3HTR2A | |
| SCHEMBL24253264 | 0.73 | CSF1R (0.33) | PARP1TLR7HRH4 | |
| SCHEMBL25632996 | 0.73 | LRRK2 (0.34) | PARP1TLR7ALDH1A1 | |
| SCHEMBL14930383 | 0.73 | PDCD1 (0.50) | PDCD1CD274HTR2CHTR2BSOD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822326-B2 | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200190058-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190058-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | PDCD1 3525/4885CD274 2589/4885HTR2C 322/4885 |
| US-10822326-B2 | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation | HBB, HBG2, MB | PDCD1 3525/4885CD274 2589/4885HTR2C 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.